StockData
Inmune Bio, Inc. logo

Inmune Bio, Inc. (INMB) stock

INMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.96+0.01 (+1.44%)

Close on Nov 17, 2026Market cap $26.64MP/E –Yield –

Inmune Bio r&d expenses

Research and development expenses are spending on new products and technology.

Inmune Bio's R&D Expenses for the twelve months ending Mar 31, 2026 was $16.66M, down 48.1% year over year. For fiscal 2025 it was $20.66M, down 37.7% from the year before. The highest annual figure on record is $33.17M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$20.66M-37.7%
FY2024Dec 31, 2024$33.17M+63.6%
FY2023Dec 31, 2023$20.27M+18.8%
FY2022Dec 31, 2022$17.07M-16.9%
FY2021Dec 31, 2021$20.54M+247.1%
FY2020Dec 31, 2020$5.92M+80.3%
FY2019Dec 31, 2019$3.28M-2.2%
FY2018Dec 31, 2018$3.35M+670.6%
FY2017Dec 31, 2017$435.36K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2026Mar 31, 2026$3.64M-52.3%
Q4 FY2025Dec 31, 2025$2.33M-68.3%
Q3 FY2025Sep 30, 2025$4.89M-51.5%
Q2 FY2025Jun 30, 2025$5.80M-17.7%
Q1 FY2025Mar 31, 2025$7.64M-12.1%
Q4 FY2024Dec 31, 2024$7.35M+22.4%
Q3 FY2024Sep 30, 2024$10.07M+68.2%
Q2 FY2024Jun 30, 2024$7.05M+70.0%
Q1 FY2024Mar 31, 2024$8.69M+110.3%
Q4 FY2023Dec 31, 2023$6.01M+76.2%
Q3 FY2023Sep 30, 2023$5.99M+16.0%
Q2 FY2023Jun 30, 2023$4.15M-1.0%
Q1 FY2023Mar 31, 2023$4.13M-4.1%
Q4 FY2022Dec 31, 2022$3.41M-51.8%
Q3 FY2022Sep 30, 2022$5.16M-20.9%
Q2 FY2022Jun 30, 2022$4.19M-6.2%
Q1 FY2022Mar 31, 2022$4.31M+73.0%
Q4 FY2021Dec 31, 2021$7.07M+280.2%
Q3 FY2021Sep 30, 2021$6.52M+175.9%
Q2 FY2021Jun 30, 2021$4.46M+394.4%
Q1 FY2021Mar 31, 2021$2.49M+214.1%
Q4 FY2020Dec 31, 2020$1.86M+114.5%
Q3 FY2020Sep 30, 2020$2.36M+102.3%
Q2 FY2020Jun 30, 2020$903.00K+42.3%
Q1 FY2020Mar 31, 2020$793.00K+29.4%
Q4 FY2019Dec 31, 2019$866.56K-12.7%
Q3 FY2019Sep 30, 2019$1.17M+78.4%
Q2 FY2019Jun 30, 2019$634.70K+120.9%
Q1 FY2019Mar 31, 2019$612.71K+489.1%
Q4 FY2018Dec 31, 2018$992.20K–
Q3 FY2018Sep 30, 2018$654.69K–
Q2 FY2018Jun 30, 2018$287.32K–
Q1 FY2018Mar 31, 2018$104.01K–

More Inmune Bio figures

See a number that looks wrong?